Author(s):
Bayan Bahnasli, Djamila Ben Hadda, Amir Balash, Mustapha Fawaz Chehna
Email(s):
bbahnasli@gmail.com , djamila.benhadda@ebla.edu.sy , amir_balash@hotmail.com , mf.chehna@gmail.com
DOI:
10.52711/0974-360X.2026.00305 
Address:
Bayan Bahnasli1, Djamila Ben Hadda2, Amir Balash3, Mustapha Fawaz Chehna1
1Department of Pharmaceutical Chemistry & Drug Control, Faculty of Pharmacy, Aleppo University, Aleppo, Syria.
2Department of Pharmaceutical Chemistry & Drug Control, Faculty of Pharmacy, Ebla University, Aleppo, Syria.
3Department of Pharmaceutical Chemistry & Drug Control, Faculty of Pharmacy, Philipps University, Marburg, Germany.
*Corresponding Author
Published In:
Volume - 19,
Issue - 5,
Year - 2026
ABSTRACT:
Numerous studies highlight the significant responsibility of CARBONIC ANHYDRASE Isoform XII in the mechanisms underlying the onset and progression of cancer. Our research focuses on the synthesis of Quinoline-Sulfonamides, which are compounds designed to inhibit this enzyme, a key player in cancer development. Using Molegro Virtual Docker (MVD), we conducted molecular modeling of these compounds, targeting Carbonic Anhydrase Isoform XII, and calculated their binding energies to identify the most promising candidate. Among the compounds studied, compound 1..e exhibited the highest binding energy at -166.694kcal/mol in comparison to 4-propylthiobenzen sulfonamide (VD9), Which has a binding energy of -115kcal/mol , Several of these compounds were synthesized efficiently using an economical and environmentally friendly aqueous method with high yield ranging between 70 to 86%.Their physicochemical properties were studied using Marvin Sketch and structural identification were confirmed through different analytical methods, involving Mass Spectrography, Infrared Spectrography, and nuclear magnetic resonance.
Cite this article:
Bayan Bahnasli, Djamila Ben Hadda, Amir Balash, Mustapha Fawaz Chehna. Synthesis, Develop and Characterization of New Quinoline-Sulfonamides derivatives as Specific Tumer-Related CARBONIC ANHYDRASE Isoform XII Inhibitors. Research Journal Pharmacy and Technology. 2026;19(5):2121-7. doi: 10.52711/0974-360X.2026.00305
Cite(Electronic):
Bayan Bahnasli, Djamila Ben Hadda, Amir Balash, Mustapha Fawaz Chehna. Synthesis, Develop and Characterization of New Quinoline-Sulfonamides derivatives as Specific Tumer-Related CARBONIC ANHYDRASE Isoform XII Inhibitors. Research Journal Pharmacy and Technology. 2026;19(5):2121-7. doi: 10.52711/0974-360X.2026.00305 Available on: https://rjptonline.org/AbstractView.aspx?PID=2026-19-5-26
REFERENCES:
1. Angeli A., Carta F., Supuran C.T. Carbonic Anhydrases: Versatile and Useful Biocatalysts in Chemistry and Biochemistry. Catalysts. 2020; 10: 1008. doi: 10.3390/catal10091008.
2. Mishra C.B., Tiwari M., Supuran C.T. Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: Where are we today? Med. Res. Rev. 2020; 40: 2485–2565. doi: 10.1002/med.21713.
3. Taslimi P., Gulcin I., Ozgeris B., Goksu S., Tumer F., Alwasel S.H., Supuran C.T. The human carbonic anhydrase isoenzymes I and II (hCA I and II) inhibition effects of trimethoxyindane derivatives. J. Enzym. Inhib. Med. Chem. 2016; 31: 152–157. doi: 10.3109/14756366.2015.1014476.
4. Eldehna W.M., Abdelrahman M.A., Nocentini A., Bua S., Al-Rashood S.T., Hassan G.S., Bonardi A., Almehizia A.A., Alkahtani H.M., Alharbi A., et al. Synthesis, biological evaluation and in silico studies with 4-benzylidene-2-phenyl-5(4H)-imidazolone-based benzenesulfonamides as novel selective carbonic anhydrase IX inhibitors endowed with anticancer activity. Bioorganic Chem. 2019; 90: 103102. doi: 10.1016/j.bioorg.2019.103102.
5. Aggarwal M., Boone C.D., Kondeti B., McKenna R. Structural annotation of human carbonic anhydrases. J. Enzym. Inhib. Med. Chem. 2013; 28: 267–277. doi: 10.3109/14756366.2012.737323.
6. Sudagar RB, Dighole NS, Musmade DS, Jaware VM, Jain DA. Estrogen receptor modulators in breast cancer therapy. Asian J Pharm Res. 2011; 1(4): 81-86.
7. Waheed A., Sly W.S. Carbonic anhydrase XII functions in health and disease. Gene. 2017; 623: 33–40. doi: 10.1016/j.gene.2017.04.027.
8. Occhipinti R., Boron W.F. Role of Carbonic Anhydrases and Inhibitors in Acid-Base Physiology: Insights from Mathematical Modeling. Int. J. Mol. Sci. 2019; 20: 3841. doi: 10.3390/ijms20153841.
9. Provensi G., Carta F., Nocentini A., Supuran C.T., Casamenti F., Passani M.B., Fossati S. A New Kid on the Block? Carbonic Anhydrases as Possible New Targets in Alzheimer’s Disease. Int. J. Mol. Sci. 2019; 20: 4724. doi: 10.3390/ijms20194724.
10. Supuran C.T. Carbonic Anhydrases and Metabolism. Metabolites. 2018; 8: 25. doi: 10.3390/metabo8020025.
11. Fabrizi F., Mincione F., Somma T., Scozzafava G., Galassi F., Masini E., Impagnatiello F., Supuran C.T. A new approach to antiglaucoma drugs: Carbonic anhydrase inhibitors with or without NO donating moieties. Mechanism of action and preliminary pharmacology. J. Enzyme Inhib. Med. Chem. 2012; 27: 138–147. doi: 10.3109/14756366.2011.597749.
12. 12.Aggarwal M., Kondeti B., McKenna R. Anticonvulsant/antiepileptic carbonic anhydrase inhibitors: A patent review. Expert Opin. Ther. Pat. 2013; 23: 717–724. doi: 10.1517/13543776.2013.782394.
13. Soni RK, Burji PB. Tumor detection algorithm using boundary-based approach. Int J Technol.
14. Sahoo D, Maiti T, Jana M, Mandal S. Cancer treatment strategy—an overview. Asian J Pharm Tech. 2011; 1(2): 28-33.
15. Pastorekova S., Gillies R.J. The role of carbonic anhydrase IX in cancer development: Links to hypoxia, acidosis, and beyond. Cancer Metastasis Rev. 2019; 38: 65–77. doi: 10.1007/s10555-019-09799-0.
16. Chiche J., Ilc K., Laferrière J., Trottier E., Dayan F., Mazure N.M., Brahimi-Horn M.C., Pouysségur J. Hypoxia-Inducible Carbonic Anhydrase IX and XII Promote Tumor Cell Growth by Counteracting Acidosis through the Regulation of the Intracellular pH. Cancer Res. 2009; 69: 358–368. doi: 10.1158/0008-5472.CAN-08-2470.
17. Chafe S.C., Vizeacoumar F.S., Venkateswaran G., Nemirovsky O., Awrey S., Brown W.S., McDonald P.C., Carta F., Metcalfe A., Karasinska J.M., et al. Genome-wide synthetic lethal screen unveils novel CAIX-NFS1/xCT axis as a targetable vulnerability in hypoxic solid tumors. Sci. Adv. 2021; 7: eabj0364. doi: 10.1126/sciadv.abj0364.
18. Saha DB, Tamerākar A, Jana M, Mandal S. Melanoma: The Dance of Death. Asian J Pharm Res. 2011; 1(2): 34-36.
19. Okuno K., Matsubara T., Nakamura T., Iino T., Kakimoto T., Asanuma K., Matsumine A., Sudo A. Carbonic anhydrase IX enhances tumor cell proliferation and tumor progression in osteosarcoma. Onco Targets Ther. 2018; 11: 6879–6886. doi: 10.2147/OTT.S177605.
20. Tafreshi N.K., Lloyd M.C., Proemsey J.B., Bui M.M., Kim J., Gillies R.J., Morse D.L. Evaluation of CAIX and CAXII Expression in Breast Cancer at Varied O2 Levels: CAIX is the Superior Surrogate Imaging Biomarker of Tumor Hypoxia. Mol. Imaging Biol. 2016; 18: 219–231. doi: 10.1007/s11307-015-0885-x.
21. M. El-Gaby, Y. A Ammar, M. IH El-Qaliei, M. F Hussein, F. A Faraghally. (2020). Sulfonamides: Synthesis and the recent applications in Medicinal Chemistry. Egyptian Journal of Chemistry. 63(12): 5289-5327.
22. Bhusari KP, Amnerkar ND, Khedekar PB, Kale MK, Bhole RP. Synthesis of some novel 4-amino-N-(1,3-benzothiazol-2-yl)benzenesulphonamide derivatives and their in vitro antimicrobial activity. Asian J Chem Res. 2008; 1(2): 53-58.
23. Bhat H.R., Masih A., Shakya A., Ghosh S.K., Singh U.P. Design, synthesis, anticancer, antibacterial, and antifungal evaluation of 4-aminoquinoline-1,3,5-triazine derivatives. J. Heterocycl. Chem. 2020; 57: 390–399. doi: 10.1002/jhet.3791.
24. Wankhede SB, Prakash A, Chitalange SS. Simultaneous spectrophotometric estimation of ofloxacin and satranidazole in tablet dosage form. Asian J Chem Res. 2008; 1(1): 9-11.
25. Musiol, R. (2017). An overview of quinoline as a privileged scaffold in cancer drug discovery. Expert Opinion on Drug Discovery, 12(6), 583-597.
26. Mohamad M, Djamila BH, Amir B, Mustapha FC. Molecular modeling study of bis-sulfonamide derivatives synthesis targeting aromatase enzyme as anticancer. Res J Pharm Technol. 2024; 17(1): 43-50. doi:10.52711/0974-360X.2024.00008
27. Ghazal MH, Hadda DB, Trefi S, Balash A, Chehna MF. New synthetic methods of ureido-substituted benzenesulfonamides as carbonic anhydrase IX inhibitors. Res J Pharm Technol. 2023; 16(8): 3884-3890. doi:10.52711/0974-360X.2023.00640 .
28. Akili S, Ben Hadda D, Bitar Y, Najjar A, Chehna MF. Computer-aided design of novel sulfonamide derivatives as EGFR kinase inhibitors for cancer treatment. Int J Org Chem. 2021; 11(4): 171-186. doi:10.4236/ijoc.2021.114012 .
29. Hussein MH, Ibrahim A, Anan MT, Chehna MF. Synthesis of arylsulfonamides by eco-friendly method and evaluation of their anti-bacterial activity. Int J Chem Biochem Sci. 2023; 23(1): 363-371.